LFLigia de Souza Fernandes

Ligia de Souza Fernandes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ligia de Souza Fernandes has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Alécia Junia Aparecida Santos

    Laboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil

    1 shared publication
  • Elton Libério da Silva

    Laboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil

    1 shared publication
  • Flávia Do Carmo Horta Pinto

    Natural Sciences Department, Federal University of São João Del-Rei, Campus Dom Bosco, São João Del-Rei, Minas Gerais, Brazil

    1 shared publication
  • Franciele Natália Peixoto

    Laboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil

    1 shared publication
  • Gabriel Davi Marena

    Laboratório de Fungos Dimórficos Patogênicos, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil

    1 shared publication
  • Jonatas Lobato Duarte

    School of Pharmaceutical Sciences, São Paulo State University “Julio de Mesquita Filho”—(UNESP), Araraquara 14800-903, SP, Brazil

    1 shared publication

Latest Publications

  • Design of Rapamycin and Resveratrol Coloaded Liposomal Formulation for Breast Cancer Therapy

    by Leidiana Rocha dos Reis, Marcela Tavares Luiz, Rafael M Sábio, Gabriel Davi Marena, Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Ligia de Souza Fernandes, Victor H Sousa Araújo, Viviane Aline Oliveira Silva, Marlus Chorilli

    Aims: The development of rapamycin (RAP) and resveratrol (RSV) coloaded liposomes (RAP-RSV-LIP) for breast cancer therapy. Materials & methods: Liposomes were prepared using a high-pressure homogen...


  • Formulation, stability study and preclinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis

    by Lígia de Souza Fernandes, Yuri Martins Amorim, Elton Libério da Silva, Samuel Calixto Silva, Alécia Junia Aparecida Santos, Franciele Natália Peixoto, Luara Moniele Neves Pires, Raquel Yumi Sakamoto, Flávia Do Carmo Horta Pinto, Maria Virgínia Costa Scarpa, et al.

    Summary: Owing to the growing resistance among isolates of Candida species to usual antifungal agents and the well‐known therapeutic potential of curcumin, the purpose of this study was to develop and validate a vaginal formulation containing this substance and to evaluating its effectiveness in the treatment of experimental vulvovaginal candidiasis. Curcumin was incorporated in a vaginal cream in three concentrations (0.01%, 0.1% and 1.0%). The different concentrations of the cream and its controls were intravaginally administered in an immunosuppressed rat model to evaluate the efficacy in the treatment of experimental vulvovaginal candidiasis. Samples of the cream were also subjected to centrifugation and physical stability tests and an analytical method for quantification of curcumin was validated based on HPLC. The formulation was stable and the HPLC method could be considered suitable for the quantitative determination of curcumin in the cream. After 6 days of preclinical study, the number of infected animals was 1/6 in all groups treated with curcumin vaginal cream and the fungal burden showed a progressive reduction. Reduction in the inflammatory infiltrate was observed in the group treated with 1.0% cream. Vaginal cream containing curcumin could be considered a promising effective antifungal medicine in the treatment of vulvovaginal candidiasis.